Since previous reports have shown that modifying the chemical structure of Gem by PEGylation leads to significantly increased circulation time and tissue penetration in vivo and may therefore be a novel option for the improved treatment of patients with (pancreatic) cancer [22], [23], we decided as a next step to determine the effects of PolyEthyleneGlycol-bound Gem (PEG-Gem) as the extended in vivo circulation time and higher tissue penetration of PEG-Gem may generate superior effects as compared to standard Gem. Here, GEM is linked to familial pancreatic carcinoma.